⚕ GalenOps field
←

SITE005-0400

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-07-02

AEs
8
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-25 (study day 5); relationship: N

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-25 (study day 36); relationship: N

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-10-06 (study day 78); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-19 (study day 91); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-20 (study day 123); relationship: Y

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-04-08 (study day 263); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-20 (study day 275); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-22 (study day 277); relationship: Y

Data queries

No data queries.